by Statsols, on Feb 15, 2018
Statisticians are familiar with the long standing debate regarding Frequentists Vs Bayesian methodologies and the benefits (or negatives) that each present to a particular situation. However, we are now experiencing a rise in traditional frequentists using Bayesian statistics. What are the reasons behind this? While complex, we can identify two high level points.
by Statsols, on Jul 28, 2017
Following on from our previous blog post, The Most Popular Clinical Trial Drugs of 2016, we thought it would be a good idea to take a closer look at the Top 10 Corporate Clinical Trial Sponsors of 2016.
In this post, we explore these Top 10 companies, looking at their developmental histories as well as the drugs they have developed and the number of subjects required for their 2016 registered trials.
by Statsols, on Jul 20, 2017
In part 3/3 of this mini series, Head of Statistics at Statsols - Ronan Fitzpatrick - examines key trends in sample size determination which are being felt in trial design.
by Statsols, on Jul 17, 2017
In part 2/3 of this mini series, Head of Statistics at Statsols - Ronan Fitzpatrick - examines key trends in sample size determination which are being felt in trial design.
by Statsols, on Jul 6, 2017
In part 1/3 of this mini series, Head of Statistics at Statsols - Ronan Fitzpatrick - examines key trends in sample size determination which are being felt in trial design.
by Statsols, on Jun 30, 2017
Currently there are over 205,000 registered clinical trials underway throughout the globe. In 2016 over 14,000 new trials were initiated and we thought it would be useful to look at the top drugs under investigation for the year just past.
by Statsols, on Jun 19, 2017
How do you reduce sample size in clinical trials? Reducing sample size without losing power can be accomplished in one of three principles. This paper examines these methods and demonstrates 15 ways to reduce sample size in clinical trials.
by Statsols, on May 9, 2017
Why do Phase III clinical trials fail and how can we improve them? Dr. Grignolo, PhD, Corporate Vice President of PAREXEL International, the multinational life sciences consulting firm, recently examined this issue in a paper titled: Phase III Trial Failures: Costly, But Preventable.
We have reviewed this journal and brought you the primary findings as they appeared in Applied Clinical Trials Volume 25, Issue 8 and also on appliedclinicaltrialsonline.com.
